Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165540 | 0.85 | HTR2A (0.48) | HTR2AHTR2CFABP4CDK4CCND1 | |
| SCHEMBL16234644 | 0.83 | HTR2A (0.54) | HTR2AHTR2CFABP4CDK4CCND1 | |
| SCHEMBL5537950 | 0.83 | KMT2A (0.60) | HTR2AHTR2CFABP4CDK4CCND1 | |
| SCHEMBL10203425 | 0.80 | HTR2A (0.51) | HTR2AHTR2CGRIN2BFABP4CDK4 | |
| SCHEMBL19674140 | 0.79 | ATM (0.57) | HTR2AHTR2CCDK4CCND1HDAC3 | |
| SCHEMBL10165538 | 0.78 | GRIN2B (0.55) | HTR2AHTR2CGRIN2B | |
| SCHEMBL25687334 | 0.76 | HTR2A (0.54) | HTR2AHTR2CFABP4CDK4CCND1 | |
| SCHEMBL10165562 | 0.76 | KDM4E (0.43) | KMT2A | |
| SCHEMBL10165570 | 0.76 | MEN1 (0.44) | GRIN2BKMT2A | |
| SCHEMBL17676466 | 0.76 | HTR2C (0.57) | HTR2AHTR2CFABP4CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | HTR2A 720/4885HTR2C 901/4885GRIN2B 213/4885 |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | HTR2A 720/4885HTR2C 901/4885GRIN2B 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.